Healthcare
Towa Pharmaceutical Co., Ltd.(TWAPF)
Live Price
Offline$16.83
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- $194.94B
- Revenue Growth
- +13.9%
- EPS Growth
- +17.4%
- Dividend Yield
- 2.0%
Coverage: 253 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Towa Pharmaceutical Co., Ltd. (TWAPF) is a Healthcare stock with a market cap of $194.94B and listed on OTC. The stock last traded around $16.83 and up 0.0% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +13.9%, EPS growth of +17.4%, a dividend yield of 2.0%. What stands out right now is revenue +13.9%, EPS +17.4%, free cash flow +74.9% with operating margin 8.9% and ROIC 4.3%. The dividend is present but secondary, with a yield around 2.0%. Valuation is more restrained than many high-expectation growth names at P/E 9.1 and price/sales 0.7. Stock Foundry combines TWAPF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.9% vs +7.6% peer median
Operating Margin
Below sector median
+8.9% vs +19.4% peer median
P/E
Below sector median
9.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 14, 2026 with an EPS surprise of -322.9% and a revenue surprise of -6.5%.
The operating story is still moving forward
Revenue is running at +13.9% and EPS at +17.4%, with operating margin around 8.9%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | -322.9% | +0.0% | +0.0% | +0.0% |
2026 Feb 13, 2026 | +145.0% | +0.0% | +0.0% | +0.0% |
2025 Nov 10, 2025 | +86.7% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TWAPF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TWAPF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TWAPF and SPY.
Company Overview
Towa Pharmaceutical Co., Ltd.
Other OTC
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
- Leadership
- Itsuro Yoshida
- IPO Date
- Oct 21, 2009
- Employees
- 4.6k
- Street Address
- 2-11, Shinbashi-cho
- Mailing
- Osaka, 571-8580
- Region
- Osaka, JP
- Reporting Currency
- USD
- Investor Line
- 81 6 6900 9100
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 9.1
- EV/EBITDA
- 8.4
- Price/Sales
- 0.7
- Price/Book
- 1.0
Growth
- Revenue
- +13.9%
- EPS
- +17.4%
- Free Cash Flow
- +74.9%
Profitability
- Gross Margin
- 36.7%
- Operating Margin
- 8.9%
- Net Margin
- 7.9%
- ROE
- 12.0%
- ROIC
- 4.3%
Balance Sheet
- Debt/Equity
- 1.23
- Current Ratio
- 2.83
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.